CN102552990B - Degradable fallopian tube stent and preparation method thereof - Google Patents
Degradable fallopian tube stent and preparation method thereof Download PDFInfo
- Publication number
- CN102552990B CN102552990B CN201110401171.1A CN201110401171A CN102552990B CN 102552990 B CN102552990 B CN 102552990B CN 201110401171 A CN201110401171 A CN 201110401171A CN 102552990 B CN102552990 B CN 102552990B
- Authority
- CN
- China
- Prior art keywords
- medicine
- degradable
- fallopian tube
- polycaprolactone
- tube stent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a degradable fallopian tube stent and a preparation method of the degradable fallopian tube stent. The degradable fallopian tube stent is an elastic knitted tube made of a polycaprolactone filament containing an anti-inflammatory medicine and an anti-adhesion medicine. The preparation method comprises the steps of: (1) mixing polycaprolactone, the anti-inflammatory medicine and the anti-adhesion medicine, performing melt spinning at 80-200 DEG C to obtain polycaprolactone fibers; (2) knitting the polycaprolactone fibers to obtain the knitted tube and heat setting at 50-55 DEG C to obtain the degradable fallopian tube stent. The degradable fallopian tube stent distracts and isolates tubes at inflammatory parts so as to prevent adhesion. Further medicine administration or delivery is not required, and the medicine is small in dosage and released gradually and has little impact on human body. The stent can prevent adhesion of fallopian tube while eliminating inflammation.
Description
Technical field
The invention belongs to fallopian tube stent and preparation field thereof, particularly a kind of degradable fallopian tube stent and preparation method thereof.
Background technology
At present, in the infertility being caused by women's pathologic problems, there is considerable part stopped up by fallopian tube adhesion and cause.Oviducal unobstructed be one of the requisite principal element of becoming pregnant, oviducal tube chamber is narrow, the lumen diameter that narrow portion is divided only has 1～2mm.In the time there is salpingitis or pelvic inflammatory disease, oviducal narrow and umbrella end are easy to stick together or complete atresia, and like this, sperm and ovum just can not meet in tube chamber, thereby cause infertile.
Summary of the invention
Technical problem to be solved by this invention is to provide a kind of degradable fallopian tube stent and preparation method thereof, and this support struts isolation inflammation part pipeline, reaches the object that prevents adhesion; Need not take medicine in addition or administration, the dosage of medicine is little, discharges gradually, also little to the harmful effect of human body, and support can prevent fallopian tube adhesion in diminishing inflammation.
The degradable fallopian tube stent of one of the present invention, described fallopian tube stent is the elastic weaving pipe of making containing the polycaprolactone silk of antibiotic medicine and anti medicine.
Described antibiotic medicine is metronidazole (2-methyl-5-nitro-1H-imidazoles-1-ethanol), ornidazole (1-(the chloro-2-hydroxypropyl of 3-)-2-5-nitro imidazole) or secnidazole (α, 2-dimethyl-5-nitro-1H-imidazoles-1-ethanol), content is 1%～3% of braided tube gross mass.
Described anti medicine is chitosan or humic acids, and content is 0.5%～3% of braided tube gross mass.
Described chitosan is the microgranule of 0.1～1 μ m.
Described polycaprolactone silk specification is 6～300D/2～100F.
Described elastic weaving pipe diameter is 1～3mm.
The compression rebound rate of described elastic weaving pipe is greater than 99.7%.
The preparation method of a kind of degradable fallopian tube stent of the present invention, comprising:
(1), by polycaprolactone, antibiotic medicine and the blend of anti medicine, at 180～200 ℃, carry out melt spinning and obtain polycaprolactone fiber; Wherein, antibiotic medicine is 1%～3% of blend gross mass, and anti medicine is 0.5%～3% of blend gross mass;
(2) above-mentioned polycaprolactone fiber is made to braided tube through braiding, thermal finalization at 50～55 ℃, to obtain final product.
Support of the present invention is degradable, and dosage is little, and sustained drug discharges, and in diminishing inflammation, support is digestion gradually also, excretes.
beneficial effect
(1) the present invention is elastic weaving pipe, can pass through in use endoscope, sends to salpingitis tubal position and discharges, and support struts isolation inflammation part pipeline, reaches the object that prevents adhesion;
(2) the present invention is pumped into silk by the polycaprolactone that contains antibiotic medicine and anti medicine, then form through braiding; Support is degraded and is excreted gradually in fallopian tube, and in scaffold degradation, medicine constantly discharges, and medicine directly also may penetrate into fimbriae of uterine tube portion to inflammation part generation effect simultaneously;
(3) the present invention need not take medicine or administration in addition, and the dosage of medicine is little, discharges gradually, also little to the harmful effect of human body, and support can prevent fallopian tube adhesion in diminishing inflammation.
The specific embodiment
Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment are only not used in and limit the scope of the invention for the present invention is described.In addition should be understood that those skilled in the art can make various changes or modifications the present invention after having read the content of the present invention's instruction, these equivalent form of values fall within the application's appended claims limited range equally.
Embodiment 1
After 0.5 kilogram of the chitosan and 98.59 kilograms of mix homogeneously of polycaprolactone of 1 kilogram of metronidazole (2-methyl-5-nitro-1H-imidazoles-1-ethanol), particle diameter 0.1 μ m, send into spinning-drawing machine screw rod through melting mixing, controlling spinneret temperature is 190 ℃, draws the polycaprolactone fiber containing metronidazole that obtains 6d/2F.Be made into again the pipe of diameter 1.5mm by weaving method, 52 ℃ of thermal finalizations.
Its compression rebound rate is 98.1% after measured.
Embodiment 2
After 450 grams of ornidazoles (1-(the chloro-2-hydroxypropyl of 3-)-2-5-nitro imidazole), 450 grams of humic acidss and 14.1 kilograms of mix homogeneously of polycaprolactone, send into spinning-drawing machine screw rod through melting mixing, controlling spinneret temperature is 180 ℃, draws the polycaprolactone fiber containing ornidazole that obtains 300d/100F.Be made into again the pipe of diameter 3mm by weaving method, 55 ℃ of thermal finalizations.
Its compression rebound rate is 97.4% after measured.
Embodiment 3
Secnidazole (α, 2-dimethyl-5-nitro-1H-imidazoles-1-ethanol) after 500 grams, particle diameter 1 500 grams of μ m chitosan and 24 kilograms of mix homogeneously of polycaprolactone, send into spinning-drawing machine screw rod through melting mixing, controlling spinneret temperature is 200 ℃, draws the polycaprolactone fiber containing secnidazole that obtains 100d/24F.Be made into again the pipe of diameter 1mm by weaving method, 50 ℃ of thermal finalizations.
Its compression rebound rate is 97.8% after measured.
Embodiment 4
After 800 grams of metronidazoles (2-methyl-5-nitro-1H-imidazoles-1-ethanol), 300 grams of humic acidss and 30.9 kilograms of mix homogeneously of polycaprolactone, send into spinning-drawing machine screw rod through melting mixing, controlling spinneret temperature is 187 ℃, draws the polycaprolactone fiber containing metronidazole that obtains 100d/72F.Be made into again the pipe of diameter 2mm by weaving method, 55 ℃ of thermal finalizations.
Its compression rebound rate is 98.4% after measured.
Claims (5)
1. a degradable fallopian tube stent, is characterized in that: described fallopian tube stent is the elastic weaving pipe of making containing the polycaprolactone silk of antibiotic medicine and anti medicine; Wherein, antibiotic medicine is metronidazole, ornidazole or secnidazole, and content is 1%～3% of braided tube gross mass; Anti medicine is chitosan or humic acids, and content is 0.5%～3% of braided tube gross mass; The compression rebound rate of elastic weaving pipe is greater than 99.7%.
2. the degradable fallopian tube stent of one according to claim 1, is characterized in that: described chitosan is the microgranule of 0.1～1 μ m.
3. the degradable fallopian tube stent of one according to claim 1, is characterized in that: described polycaprolactone silk specification is 6～300D/2～100F.
4. the degradable fallopian tube stent of one according to claim 1, is characterized in that: described elastic weaving pipe diameter is 1～3mm.
5. a preparation method for degradable fallopian tube stent as claimed in claim 1, comprising:
(1), by polycaprolactone, antibiotic medicine and the blend of anti medicine, at 180～200 ℃, carry out melt spinning and obtain polycaprolactone fiber; Wherein, antibiotic medicine is 1%～3% of blend gross mass, and anti medicine is 0.5%～3% of blend gross mass;
(2) above-mentioned polycaprolactone fiber is made to braided tube through braiding, thermal finalization at 50～55 ℃, to obtain final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110401171.1A CN102552990B (en) | 2011-12-06 | 2011-12-06 | Degradable fallopian tube stent and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110401171.1A CN102552990B (en) | 2011-12-06 | 2011-12-06 | Degradable fallopian tube stent and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102552990A CN102552990A (en) | 2012-07-11 |
| CN102552990B true CN102552990B (en) | 2014-05-28 |
Family
ID=46400436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110401171.1A Expired - Fee Related CN102552990B (en) | 2011-12-06 | 2011-12-06 | Degradable fallopian tube stent and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102552990B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109498849B (en) * | 2018-06-25 | 2020-04-24 | 北京百利康生化有限公司 | Medical fallopian tube support device |
| CN112535767A (en) * | 2019-09-20 | 2021-03-23 | 江苏启灏医疗科技有限公司 | Preparation method of fallopian tube scaffold |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1529653A (en) * | 2001-05-16 | 2004-09-15 | �й���ѧԺ���ݻ�ѧ�о��� | Biodegradable and/or biological absorbing fiber product and its use in medical application |
| WO2006114004A2 (en) * | 2005-04-25 | 2006-11-02 | Hafeez, Naila | A remote controlled tubular implant device and implanting apparatus |
| CN101380484A (en) * | 2008-06-30 | 2009-03-11 | 李捷 | Medical operation suture thread |
-
2011
- 2011-12-06 CN CN201110401171.1A patent/CN102552990B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1529653A (en) * | 2001-05-16 | 2004-09-15 | �й���ѧԺ���ݻ�ѧ�о��� | Biodegradable and/or biological absorbing fiber product and its use in medical application |
| WO2006114004A2 (en) * | 2005-04-25 | 2006-11-02 | Hafeez, Naila | A remote controlled tubular implant device and implanting apparatus |
| CN101380484A (en) * | 2008-06-30 | 2009-03-11 | 李捷 | Medical operation suture thread |
Non-Patent Citations (2)
| Title |
|---|
| 刘静等.进口医用可吸收缝合线做支架用于输卵管子宫角植入术的体会.《中国计划生育学杂志》.2003,(第7期),第434-435. |
| 进口医用可吸收缝合线做支架用于输卵管子宫角植入术的体会;刘静等;《中国计划生育学杂志》;20031231(第7期);第435页右栏倒数第2段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102552990A (en) | 2012-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012521997A5 (en) | ||
| Costa et al. | Endoscopic study of the intranasal ostium in external dacryocystorhinostomy postoperative. Influence of saline solution and 5-fluorouracil | |
| AU2014363599B2 (en) | Orally disintegrating solid dosage unit containing an estetrol component | |
| CN102552990B (en) | Degradable fallopian tube stent and preparation method thereof | |
| HRP20191049T1 (en) | (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentalfuoromethyl)estra-4,9-dien-3-one for use in the treatment of diseases | |
| NZ592719A (en) | PHARMACEUTICAL FORMULATION 514 comprising 4-[3-( 4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one | |
| CN101564557A (en) | Method for preparing antibiosis self-expanding material of one-off cervix dilator | |
| CN105411996B (en) | A kind of preparation method of polylactic acid base load medicine controlled-release material | |
| Santos et al. | Histological analysis of biocompatibility of ionomer cements with an acid-base reaction | |
| Hwang et al. | Real-time in vivo monitoring of viable stem cells implanted on biocompatible scaffolds | |
| JP2013520271A5 (en) | ||
| CN107217322B (en) | Drug-loaded filament and preparation method thereof | |
| CN101897758A (en) | Traditional Chinese medicinal composition for curing animal womb inflammation and other postpartum diseases | |
| CN102058876A (en) | Cervix antibacterial repair complex and preparation method thereof | |
| CN102028569A (en) | Degradable bracket with radiotherapy and chemotherapy synergistic effect and preparation method thereof | |
| CN103028147B (en) | Fiber-based non-woven biodegradable ureteral stent tube and preparation method thereof | |
| CN105855553B (en) | A kind of preparation method of porous tantalum material for oral cavity implantation | |
| Zhu et al. | Effect of beta-tricalcium phosphate/poly-l-lactide composites on radial bone defects of rabbit | |
| Yaman et al. | The role of NMDA glutamate receptors in lung injury caused by chronic long-term intermittent hypobaric hypoxia | |
| CN106580386B (en) | A kind of absorbable uterine cavity sacculus | |
| CN104323982B (en) | A kind of suppository containing high elastic modulus viscose rayon and its preparation method | |
| CN102835562A (en) | Anti-inflammation premix for preventing respiratory disease | |
| CN109674903A (en) | One curing hysteromyoma, uterus adenomyosis, cervical polyp, HPV therapeutic agent | |
| CN204133574U (en) | Intrauterine adhesion block device | |
| CN102835567A (en) | Traditional Chinese medicine-containing feed premix for preventing respiratory disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140528 Termination date: 20161206 |